ArticleDiagnostic pathology2013
Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies.
Article in Diagnostic pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pooled it
- Advances in Duchenne Muscular Dystrophy: Diagnostic Techniques and Dystrophin Domain Insights.International journal of molecular sciences · 2025Review
- A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.Nature communications · 2022Article
- Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by immunohistochemistry.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Article
- Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients.Journal of thoracic disease · 2019Article
- EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.BMC pulmonary medicine · 2018Article
- [Clinical Significance and Mechanism of PI3K p110β Overexpression in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017Article
- Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry.Molecular and clinical oncology · 2017Article
- [Influence of Immunohistochemistry Scoring Criteria in Detecting EGFR Mutations].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.Cancer research and treatment · 2015Article
- Article
- [Immunohistochemical detections of EGFR status in NSCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- [Immunohistochemical detections of EGFR mutations in NSCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
- Glia activation and its role in oxidative stress.Metabolic brain disease · 2014Article
- Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma.Diagnostic pathology · 2014Article
- Whole DNA methylome profiling in lung cancer cells before and after epithelial-to-mesenchymal transition.Diagnostic pathology · 2014Article
- Serum level of DKK-1 and its prognostic potential in non-small cell lung cancer.Diagnostic pathology · 2014Article
- Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.Diagnostic pathology · 2014Article
- Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.Diagnostic pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent development of antibodies specific for the major hotspot mutations in the epidermal growth factor receptor (EGFR), L858R and E746_A750del, may provide an opportunity to use immunohistochemistry (IHC) as a screening test for EGFR gene mutations. This study was designed to optimize the IHC protocol and the criteria for interpretation of the results using DNA sequencing as the gold-standard.
methodsTumor sections from fifty lung adenocarcinoma specimens from Chinese patients were immunostained using L858R and E746_A750del-specific antibodies using three different antigen retrieval solutions, and the results were evaluated using three different sets of criteria. The same specimens were used for DNA purification and analysis of EGFR gene mutations.
resultsIn this study the optimal buffer for antigen retrieval was EDTA (pH 8.0), and the optimal scoring method was to call positive results when there was moderate to strong staining of membrane and/or cytoplasm in >10% of the tumor cells. Using the optimized protocol, L858R-specific IHC showed a sensitivity of 81% and a specificity of 97%, and E746_A750del-specific IHC showed a sensitivity of 59% and a specificity of 100%, both compared with direct DNA analysis. Additionally, the mutant proteins as assessed by IHC showed a more homogeneous than heterogeneous pattern of expression.
conclusionsOur data demonstrate that mutation-specific IHC, using optimized procedures, is a reliable prescreening test for detecting EGFR mutations in lung adenocarcinoma. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2059012601872392.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.